Evidence map›Paper›PMID 38188250›Full record

ArticleUpsala journal of medical sciences2023

A temporary regulation to manage an impending shortage due to extraordinary prescribing patterns of chloroquines observed during early phase of COVID-19 epidemic.

Karl-Mikael Kälkner, Anders Sundström, Maria Juhasz Haverinen, Kenneth Nordback, Veronica Arthurson, Björn Zethelius, Rickard Ljung

Open access · diamondAbstract read
In one paragraph

Article in Upsala journal of medical sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 72% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Karl-Mikael KälknerSwedish Medical Products Agency, Uppsala, Sweden.
Anders SundströmSwedish Medical Products Agency, Uppsala, Sweden.
Maria Juhasz HaverinenRegion Stockholm, Stockholm, Sweden.
Kenneth NordbackSwedish Medical Products Agency, Uppsala, Sweden.
Veronica ArthursonSwedish Medical Products Agency, Uppsala, Sweden.
Björn ZetheliusSwedish Medical Products Agency, Uppsala, Sweden.
Rickard LjungSwedish Medical Products Agency, Uppsala, Sweden.
Medical Products Agency · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Chloroquine and hydroxychloroquine (C/HC) received considerable international media attention due to anticipated treatment effect in COVID-19. This led to increased prescriptions threatening to generate product shortages for patients prescribed within approved indications.We evaluated effects of a temporary regulation mandating pharmacies to only dispense C/HC prescribed by physicians with defined specialties. Methods: Data from Region Stockholm, which include 2.4 out of 10 million Sweden's population, were used. Weekly time trends of prescriptions and requisitions of C/HC by prescriber's workplace during January to April 2020 were followed. Results: Numbers of unique individuals with filled prescriptions of chloroquine increased tenfold and of hydroxychloroquine more than threefold from January to March. In the first week of April, filled prescriptions of C/HC dropped. In the later weeks of April, the number of filled prescriptions was back at similar levels as before the SARS-CoV-2 outbreak.During January and February, specialists in rheumatology accounted for 686 out of all 979 prescriptions dispensed (70.1%) of C/HC. In March, a large proportion of prescriptions dispensed were from specialists not usually prescribing C/HC, and rheumatology accounted for 628 out of all 1,639 prescriptions (38.3%). In April, specialists in rheumatology accounted for 386 out of all 641 prescriptions dispensed (60.0%). Conclusion: After an observed increase in prescriptions of C/HC, a temporary regulation was introduced on 2nd April 2020 to reduce prescriptions from specialists not usually prescribing C/HC to avoid shortages for patients within approved indications. Subsequently, dispensed prescriptions decreased from April and remained at pre-COVID-19 levels thereafter.

Indexed as

COVID-19HydroxychloroquineChloroquineCOVID-19 Drug TreatmentHumansSARS-CoV-2ChloroquineHydroxychloroquinechloroquineCOVID-19 epidemichydroxychloroquineimpending shortageprescribing patternsTemporary regulation

Identifiers

PMID38188250
PMCPMC10770639
OpenAlexW4390528441

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.